Exscientia Ltd ADR

NASDAQ EXAI

Data sourced from

and

Daily

Download Data

Exscientia Ltd ADR Market Capitalization on June 03, 2024: USD 684.51 M

Exscientia Ltd ADR Market Capitalization is USD 684.51 M on June 03, 2024, a -28.32% change year over year. Market capitalization is a financial metric that represents the total value of a publicly traded company. It is calculated by multiplying the current share price of a company by the total number of outstanding shares. Market capitalization is used to assess the size and relative value of a company in the stock market. It provides investors with an idea of the company's overall worth and is often used as a basis for comparing companies within the same industry or sector. A higher market capitalization generally indicates a larger, more established company.

Exscientia Ltd ADR 52-week high Market Capitalization is USD 1.11 B on July 31, 2023, which is 62.45% above the current Market Capitalization.
Exscientia Ltd ADR 52-week low Market Capitalization is USD 501.55 M on April 25, 2024, which is -26.73% below the current Market Capitalization.
Exscientia Ltd ADR average Market Capitalization for the last 52 weeks is USD 742.34 M.

NASDAQ: EXAI

Exscientia Ltd ADR

CEO	Prof. Andrew L. Hopkins DPHIL, FRSE FRSC
IPO Date	Oct. 1, 2021
Location	United Kingdom
Headquarters	The SchrOedinger Building, Oxford, United Kingdom, OX4 4GE
Employees	483
Sector	Healthcare
Industry	Biotechnology

Description

Exscientia plc, an artificial intelligence (AI) driven Pharma-tech company, engages in design and develop differentiated medicines for diseases with high unmet patient needs. The company's lead product candidate GTAEXS617, a CDK7 inhibitor, which is currently in a Phase 1/2 trial to manage the potential toxicities associated with CDK7 as well as optimizing pharmacokinetics for maximizing on-target efficacy. It is also involved in the development of EXS4318, a PKC-theta inhibitor, under Phase 1 clinical trial for inflammation and immunology indications; EXS74539, a LSD1 inhibitor, under preclinical studies for SCLC, AML, and potential additional indications; EXS73565, a MALT1 inhibitor, under preclinical studies for multiple hematology indications; and DSP-0038, currently in Phase 1 studies. The company has collaboration agreements with Merck KGaA, Bristol Myers Squibb, Sanofi, Bill & Melinda Gates Foundation, Charité " Universitätsmedizin Berlin, Rallybio, and GT Apeiron Therapeutics. Exscientia plc was founded in 2012 and is headquartered in Oxford, the United Kingdom.

Key trends